Compare Under Armour Inc Class A (UA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Zoetis Inc — how do they compare? Under Armour Inc Class A trades at $4.82 (market cap $2.08B), while Zoetis Inc trades at $73.71 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 14.6× Under Armour Inc Class A's market cap, and Zoetis Inc pays a 2.89% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| UA | ZTS | |
|---|---|---|
Market Cap | $2.08B | $30.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $150.61 |
52-Week Low | $3.96 | $71.91 |
Enterprise Value | $3.06B | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.95, down 3.32% today, reflecting ongoing challenges. The stock is technically bearish with weak moving averages, while fundamentals show revenue declining to $5.16B in 2025 and a net loss of -$201.27M. Negative cash flow and high debt levels add pressure, though a P/S ratio of 0.42 suggests potential undervaluation. Recent news highlights continued revenue declines and lowered guidance, signaling brand and demand headwinds.
The outlook remains cautious due to persistent losses and competitive pressures. While analyst sentiment is mixed with 40% buy ratings, risks from execution missteps and weak consumer demand outweigh near-term opportunities. Investors should focus on margin improvement and debt management for any sustainable recovery.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
